All
Personalized Therapy Helps Tailor Treatment for GIST
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Can ctDNA Help Guide Surgical Decision Making in Breast Cancer
Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment.
Self-Advocacy Can Help Patients Navigate Cancer Treatment Challenges
Speaking up during cancer treatment helped one patient manage side effects, address insurance issues and stay productive throughout chemotherapy.
Experts Walk Through Recent Hematologic Malignancy Treatment Updates
Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.
Breaking Down the Impact of SERENA-6 for Some With Breast Cancer
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
Why I Don’t Call Myself a Survivor With Metastatic Breast Cancer
Living with metastatic breast cancer, I find it hard to relate to the term “survivor.”
Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.
Exploring Palliative and Curative Radiation for Lung Cancer
Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.
When a “Thinking of You” Card Isn’t the Right Support for a Patient
Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.
FDA Approves Monjuvi With Revlimid and Rituxan for Follicular Lymphoma
The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.
Recent SCLC Data May Impact How Patients Are Treated Day-to-Day
Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.
I’m a Survivor: The Day I Finally Believed It
I finally felt like a survivor the day I heard my 18-month scans were clear, shifting from fear to faith and realizing I was not just surviving — I was thriving.
The Person Behind Their Diagnosis: Understanding the Patient
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer
Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.
ctDNA-Guided Therapy May Improve Breast Cancer Outcomes
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
From Navigating the Unknown to Building a Movement: My DCIS Journey
The bad news is you have ductal carcinoma in situ. The good news is that DCIS is the best type of breast cancer to get.
How Insurance Red Tape Threatens Timely Cancer Care
A study explores how prior authorization requirements; coverage stoppages and other red tape can generate barriers to life saving therapies in cancer care.
When Cancer and COVID Collide: The Diagnosis That Changed It All
I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a statistic.
Understanding the Importance of the DESTINY-Breast09 Trial in HER2+ Breast Cancer
Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic breast cancer should know.
Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
New Treatment Options Emerging Across Lung Cancer Subtypes
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
Cancer Recurrence, Getting Past the Anxiety
If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.
Understanding the Whole Person Behind their Cancer Diagnosis
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
Rybrevant Combo Improves Lung Cancer Outcomes After Tagrisso Failure
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.
How Scars and Journaling Helped Me Embrace Life After Colon Cancer
I became a colon cancer survivor after my 2020 diagnosis, and I share how my scars, mindset shifts and journaling helped me embrace this second chance.
Explaining Brain Cancer and Metastases Updates for Patients
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
FDA Grants Fast Track Designation to Nuvisertib in Myelofibrosis
The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which demonstrated symptom relief in patients.
Delving Into Brain Cancer Treatment Takeaways Following ASCO 2025
The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.
Running a Race I Never Chose: Life During Cancer
I feel unprepared and overwhelmed after my breast cancer diagnosis, facing treatment like a race, hoping for the strength to reach the finish.
